Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
MHLW Panel Approves List of “Stable Supply Medicines”; Pricing to Become Topic of Discussions
A panel of the Ministry of Health, Labor and Welfare (MHLW) on March 26 approved a list of 506 APIs deemed to be essential in clinical practices, called “stable supply medicines.” The panel on stable drug supplies was launched in March…
To read the full story
Related Article
- Japan Finalizes Designation of 762 “Supply-Ensured Medicines”
October 28, 2025
- Japan to Expand List of “Stable Supply Medicines” to 759 APIs, Adding Vaccines and Blood Products
August 28, 2025
- MHLW Working Group Sets Policy for Revising List of “Stable Supply Medicines”
August 18, 2025
- MHLW Working Group Begins Discussions to Update List of “Stable Supply Medicines”
May 22, 2025
- MHLW to Update List of “Stable Supply Medicines” Eyeing Expansion
October 25, 2024
- Legal Initiatives Necessary to Ensure Stable Drug Supplies: MHLW Official
March 28, 2022
- MHLW Unveils List of “Stable Supply Medicines”
March 2, 2021
- Working Group Agrees to Designate 10-20 “Stable Supply Medicines” as Top Priority Drugs
November 4, 2020
- 1st Working Group Meeting for Prioritization of “Stable Supply Medicines” Set for Early November
October 26, 2020
REGULATORY
- LDP Wins Landslide Victory in Lower House Election; Ex-Lawmakers Return as Centrists Routed
February 9, 2026
- MHLW Panel Deems 10 “Drug Loss” Products as High-Need, to Seek Development
February 9, 2026
- MHLW to Allow OTC Drugs to Match Prescription Doses under Specific Conditions
February 5, 2026
- Japan Launches Biotechnology Working Group, Roadmap Draft Due in April
February 4, 2026
- Japan Panel Backs Nonprescription Switch of Second Emergency Contraceptive
February 4, 2026
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…